Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RCUS |
---|---|---|
09:32 ET | 7097 | 16.39 |
09:33 ET | 4344 | 16.17 |
09:35 ET | 691 | 16.11 |
09:37 ET | 3744 | 16.22 |
09:39 ET | 1430 | 16.6 |
09:44 ET | 100 | 16.525 |
09:46 ET | 200 | 16.505 |
09:48 ET | 1200 | 16.7 |
09:50 ET | 8439 | 16.77 |
09:51 ET | 1730 | 16.862931 |
09:53 ET | 100 | 16.96 |
09:55 ET | 7190 | 16.995 |
09:57 ET | 3810 | 16.905 |
10:00 ET | 2220 | 17.07 |
10:02 ET | 677 | 16.965 |
10:04 ET | 1639 | 16.96 |
10:06 ET | 6255 | 17.01 |
10:08 ET | 550 | 16.925 |
10:09 ET | 540 | 16.92 |
10:11 ET | 2150 | 16.975 |
10:13 ET | 2720 | 17.1 |
10:15 ET | 18203 | 16.89 |
10:18 ET | 2324 | 16.885 |
10:20 ET | 996 | 16.93 |
10:24 ET | 1278 | 16.88 |
10:26 ET | 4178 | 16.92 |
10:27 ET | 300 | 16.885 |
10:29 ET | 3462 | 16.96 |
10:31 ET | 984 | 17.01 |
10:33 ET | 573 | 16.98 |
10:36 ET | 1500 | 17 |
10:38 ET | 2061 | 17.09 |
10:40 ET | 1050 | 17.09 |
10:42 ET | 2041 | 17 |
10:44 ET | 1700 | 17.005 |
10:45 ET | 15525 | 17.06 |
10:47 ET | 520 | 17.08 |
10:49 ET | 400 | 17.04 |
10:51 ET | 804 | 17.07 |
10:54 ET | 600 | 16.98 |
10:56 ET | 300 | 16.99 |
10:58 ET | 1614 | 17.01 |
11:00 ET | 700 | 17.04 |
11:02 ET | 1690 | 17.0742 |
11:03 ET | 5070 | 17.15 |
11:05 ET | 3299 | 17.205 |
11:07 ET | 884 | 17.1832 |
11:09 ET | 1101 | 17.19 |
11:12 ET | 661 | 17.18 |
11:14 ET | 266 | 17.18 |
11:16 ET | 5375 | 17.085 |
11:20 ET | 921 | 17.05 |
11:21 ET | 100 | 17.065 |
11:23 ET | 7496 | 17.18 |
11:25 ET | 557 | 17.22 |
11:27 ET | 326 | 17.24 |
11:30 ET | 5169 | 17.25 |
11:32 ET | 300 | 17.25 |
11:36 ET | 6668 | 17.235 |
11:38 ET | 652 | 17.22 |
11:39 ET | 732 | 17.22 |
11:41 ET | 1114 | 17.21 |
11:45 ET | 650 | 17.2131 |
11:48 ET | 2042 | 17.23 |
11:50 ET | 5232 | 17.235 |
11:52 ET | 2865 | 17.255 |
11:54 ET | 2100 | 17.25 |
11:56 ET | 641 | 17.28 |
11:57 ET | 3635 | 17.3 |
11:59 ET | 400 | 17.3 |
12:01 ET | 1185 | 17.33 |
12:03 ET | 685 | 17.35 |
12:06 ET | 2915 | 17.38 |
12:08 ET | 1100 | 17.36 |
12:10 ET | 801 | 17.34 |
12:12 ET | 1682 | 17.31 |
12:14 ET | 1571 | 17.3 |
12:19 ET | 627 | 17.3 |
12:21 ET | 4726 | 17.24 |
12:24 ET | 2977 | 17.28 |
12:26 ET | 675 | 17.3 |
12:28 ET | 1322 | 17.265 |
12:30 ET | 2102 | 17.2 |
12:32 ET | 1300 | 17.195 |
12:33 ET | 2573 | 17.2 |
12:35 ET | 716 | 17.2 |
12:37 ET | 300 | 17.2 |
12:39 ET | 1444 | 17.2 |
12:42 ET | 3209 | 17.165 |
12:44 ET | 694 | 17.17 |
12:46 ET | 5451 | 17.2 |
12:48 ET | 1514 | 17.14 |
12:50 ET | 2527 | 17.185 |
12:51 ET | 2263 | 17.185 |
12:53 ET | 1471 | 17.2 |
12:55 ET | 2988 | 17.16 |
12:57 ET | 1416 | 17.15 |
01:00 ET | 500 | 17.15 |
01:02 ET | 3110 | 17.165 |
01:04 ET | 259 | 17.175 |
01:06 ET | 749 | 17.185 |
01:08 ET | 200 | 17.2 |
01:09 ET | 1375 | 17.2 |
01:11 ET | 3003 | 17.185 |
01:13 ET | 200 | 17.195 |
01:15 ET | 200 | 17.22 |
01:18 ET | 200 | 17.185 |
01:20 ET | 3721 | 17.15 |
01:22 ET | 3004 | 17.15 |
01:24 ET | 300 | 17.15 |
01:26 ET | 5308 | 17.15 |
01:27 ET | 500 | 17.15 |
01:29 ET | 408 | 17.15 |
01:31 ET | 3161 | 17.15 |
01:33 ET | 1508 | 17.15 |
01:36 ET | 3436 | 17.165 |
01:38 ET | 100 | 17.165 |
01:40 ET | 1057 | 17.19 |
01:44 ET | 318 | 17.18 |
01:45 ET | 3500 | 17.15 |
01:47 ET | 200 | 17.15 |
01:49 ET | 310 | 17.15 |
01:51 ET | 1100 | 17.15 |
01:54 ET | 4059 | 17.07 |
01:56 ET | 1433 | 17.07 |
01:58 ET | 1378 | 17.06 |
02:00 ET | 100 | 17.03 |
02:02 ET | 8114 | 16.97 |
02:03 ET | 2236 | 16.92 |
02:05 ET | 1702 | 16.96 |
02:07 ET | 2616 | 16.9 |
02:09 ET | 400 | 16.9 |
02:12 ET | 500 | 16.895 |
02:14 ET | 4993 | 16.99 |
02:16 ET | 6598 | 17.08 |
02:20 ET | 227 | 17.05 |
02:21 ET | 610 | 17.01 |
02:23 ET | 800 | 17.06 |
02:25 ET | 1061 | 17.1 |
02:27 ET | 5905 | 17.12 |
02:30 ET | 350 | 17.1104 |
02:32 ET | 468 | 17.13 |
02:34 ET | 396 | 17.1111 |
02:36 ET | 300 | 17.15 |
02:38 ET | 100 | 17.15 |
02:39 ET | 1331 | 17.09 |
02:41 ET | 100 | 17.105 |
02:43 ET | 300 | 17.08 |
02:45 ET | 300 | 17.13 |
02:48 ET | 200 | 17.13 |
02:50 ET | 3081 | 17.11 |
02:52 ET | 681 | 17.09 |
02:54 ET | 7456 | 17.115 |
02:56 ET | 744 | 17.12 |
02:59 ET | 5878 | 17.02 |
03:01 ET | 1800 | 17.045 |
03:03 ET | 400 | 17.03 |
03:06 ET | 1896 | 17.03 |
03:08 ET | 3236 | 17.03 |
03:10 ET | 868 | 17 |
03:12 ET | 4509 | 17 |
03:14 ET | 800 | 17.005 |
03:15 ET | 3080 | 16.96 |
03:17 ET | 3189 | 16.955 |
03:19 ET | 2367 | 16.93 |
03:21 ET | 2600 | 16.87 |
03:24 ET | 6693 | 16.93 |
03:26 ET | 2008 | 16.945 |
03:28 ET | 12615 | 16.99 |
03:30 ET | 1263 | 16.98 |
03:32 ET | 4015 | 17 |
03:33 ET | 4450 | 16.99 |
03:35 ET | 2453 | 17.04 |
03:37 ET | 4235 | 17.08 |
03:39 ET | 2420 | 17.065 |
03:42 ET | 200 | 17.07 |
03:44 ET | 4121 | 17.01 |
03:46 ET | 13056 | 17 |
03:48 ET | 11219 | 16.955 |
03:50 ET | 5542 | 16.99 |
03:51 ET | 5330 | 17.02 |
03:53 ET | 4073 | 17.03 |
03:55 ET | 4632 | 17.07 |
03:57 ET | 28840 | 17.085 |
04:00 ET | 191971 | 17.1 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Arcus Biosciences Inc | 1.6B | -5.4x | --- |
Travere Therapeutics Inc | 1.7B | -4.3x | --- |
Ardelyx Inc | 1.3B | -17.9x | --- |
Nurix Therapeutics Inc | 1.5B | -7.2x | --- |
Arvinas Inc | 1.7B | -5.3x | --- |
Arcutis Biotherapeutics Inc | 1.5B | -7.0x | --- |
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6B |
---|---|
Revenue (TTM) | $263.0M |
Shares Outstanding | 91.5M |
Arcus Biosciences Inc does not pay a dividend. | |
Beta | 0.85 |
EPS | $-3.15 |
Book Value | $6.12 |
P/E Ratio | -5.4x |
Price/Sales (TTM) | 5.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -120.91% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.